Navigation Links
Cancer Care Compromised by Cost

A team of researchers has recommended that, in order to implement better cancer care to patients certain reforms have to be mustered immediately. //Their views were published in the British Medical journal. The team of researchers opined that the National Institute for Health and Clinical Excellence (NICE) should amend some of their modes of action, in order to cater to the immediate needs of cancer patients. More planning is essential to ensure that those battling with cancer shall be assured supply of life saving drugs through the NHS.

Last August NICE, had pointed that unless local Trusts mobilized funds, they would be unable to cover the entire costs of drugs like Herceptin to patients. Herceptin is a drug that can fight cancer by targeting a protein, the HER2 protein, which can trigger off tumors. Almost 20% of breast cancers are noted to be HER2 positive. NICE has ruled that, all breast cancer patients that are HER2 would benefit from treatment with Herpecitin following chemotherapy, surgery or radiation therapy. However following this ruling, no move has been made by NICE to indicate where the extra funds should be recovered from. Unless federal funds are released, cancer patient who cannot afford the treatment cannot get the benefits.

Doctors from Norwich University Hospital NHS Trust studied the data linked to the bulk of cancer patients receiving treatment at their hospital. Their findings show that 1.9 million pounds are required to make the drug Herpecitin available to all patients who need the drug. Costs cannot be contained with the treatment alone. The projected expense can be covered only if the equally important palliative care or chemotherapy is done away with, they concluded.

There is no conclusive data that shows that there are any long term benefits that the drug Herpecetin, promises except that it is the drug of choice at this moment. That is not a reliable reason to deny patients conventional treatment and sw itch over to Herpecitin, which is not cost effective either, say doctors.

Doctors who were part of the study opine that, in an ideal situation the government should back up their decision by providing the source of funding for newer drugs. Suggestions have been framed, urging the Department of Health to keep aside money to fund NICE.
MST
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2017)... Wisconsin (PRWEB) , ... May 24, 2017 , ... ... in clean label food ingredient solutions for the food and beverage industry offers ... in food ingredient statements during the purchasing decision process. As a result, labels ...
(Date:5/23/2017)... York City (PRWEB) , ... May 23, 2017 ... ... (EHR), Population Health and Clinical Integration company, announced today that its iClinic ... Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information resource ... the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders ... healthcare industry today. , Out of more than 500 submissions, 100 winners were ...
(Date:5/23/2017)... Santa Rosa, California (PRWEB) , ... May 23, ... ... population health management (PHM) technology and a 2017 Best in KLAS category winner, ... an advantageous market position to extend and enhance its technology platform and product ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a ... in building collagen and elastin in their face, neck, and body through a ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
Breaking Medicine Technology: